M
Michael Aviram
Researcher at Technion – Israel Institute of Technology
Publications - 489
Citations - 32705
Michael Aviram is an academic researcher from Technion – Israel Institute of Technology. The author has contributed to research in topics: Cholesterol & Lipoprotein. The author has an hindex of 94, co-authored 479 publications receiving 31141 citations. Previous affiliations of Michael Aviram include University of Tromsø & Steward Health Care System.
Papers
More filters
Journal ArticleDOI
Changes in lipoproteins and subfractions following oophorectomy and oestrogen replacement in peri-menopausal women.
TL;DR: Serum cholesterol concentrations in lipoprotein fractions and subfractions were determined in 11 peri-menopausal women both before and after bilateral oophorectomy, as well as 60 days after commencement of oral oestradiol replacement therapy.
Journal ArticleDOI
Increased concentration of high density lipoprotein in plasma and decreased platelet aggregation in primary biliary cirrhosis
TL;DR: The abnormal lipoproteins in these patients may contribute to their abnormal in vitro platelet aggregation, and little correlation between lipoprotein disorders and clinical condition was found.
Journal ArticleDOI
Paraoxonase 1 interactions with atherosclerotic lesions and arterial macrophages protect against foam cell formation and atherosclerosis development
TL;DR: It is of interest that, similarly to HDL-associated PON1 antioxidant properties, PON2 possesses similar antioxidant/antiatherogenic characteristics towards arterial macrophage foam cells, the hallmark of early atherogenesis.
Journal ArticleDOI
Intralipid infusion in patients with familial hypercholesterolemia. Effect of serum and plasma lipoproteins on platelet aggregation and on macrophage cholesterol metabolism.
TL;DR: It is concluded that intralipid infusion abolishes serum ability to stimulate cholesterol esterification in cultured macrophages, and exhibits inhibitory effects upon platelet aggregation.
Journal ArticleDOI
Omapatrilat decreased macrophage oxidative status and atherosclerosis progression in atherosclerotic apolipoprotein E-deficient mice.
Tony Hayek,Shadi Hamoud,Shlomo Keidar,Elsa Pavlotzky,Raymond Coleman,Michael Aviram,Marielle Kaplan +6 more
TL;DR: Omapatrilat has a substantial anti-atherosclerotic effect, which can be related not only to BP reduction but also to its ability to reduce oxidative stress in atherosclerosis E0 mice.